Cargando…
Response and resistance to BET bromodomain inhibitors in triple negative breast cancer
Triple negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy(1-3). BET bromodomain inhibitors, which have shown efficacy in several models of cancer(4-6), have not been evaluated in TNBC. These inhibitors displace BET bromodomain pr...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854653/ https://www.ncbi.nlm.nih.gov/pubmed/26735014 http://dx.doi.org/10.1038/nature16508 |
_version_ | 1782430246134349824 |
---|---|
author | Shu, Shaokun Lin, Charles Y. He, Housheng Hansen Witwicki, Robert M. Tabassum, Doris P. Roberts, Justin M. Janiszewska, Michalina Huh, Sung Jin Liang, Yi Ryan, Jeremy Doherty, Ernest Mohammed, Hisham Guo, Hao Stover, Daniel G. Ekram, Muhammad B. Brown, Jonathan D'Santos, Clive Krop, Ian E. Dillon, Deborah McKeown, Michael Ott, Christopher Qi, Jun Ni, Min Rao, Prakash K. Duarte, Melissa Wu, Shwu-Yuan Chiang, Cheng-Ming Anders, Lars Young, Richard A. Winer, Eric Letai, Antony Barry, William T. Carroll, Jason S. Long, Henry Brown, Myles Liu, X. Shirley Meyer, Clifford A. Bradner, James E. Polyak, Kornelia |
author_facet | Shu, Shaokun Lin, Charles Y. He, Housheng Hansen Witwicki, Robert M. Tabassum, Doris P. Roberts, Justin M. Janiszewska, Michalina Huh, Sung Jin Liang, Yi Ryan, Jeremy Doherty, Ernest Mohammed, Hisham Guo, Hao Stover, Daniel G. Ekram, Muhammad B. Brown, Jonathan D'Santos, Clive Krop, Ian E. Dillon, Deborah McKeown, Michael Ott, Christopher Qi, Jun Ni, Min Rao, Prakash K. Duarte, Melissa Wu, Shwu-Yuan Chiang, Cheng-Ming Anders, Lars Young, Richard A. Winer, Eric Letai, Antony Barry, William T. Carroll, Jason S. Long, Henry Brown, Myles Liu, X. Shirley Meyer, Clifford A. Bradner, James E. Polyak, Kornelia |
author_sort | Shu, Shaokun |
collection | PubMed |
description | Triple negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy(1-3). BET bromodomain inhibitors, which have shown efficacy in several models of cancer(4-6), have not been evaluated in TNBC. These inhibitors displace BET bromodomain proteins such as BRD4 from chromatin by competing with their acetyllysine recognition modules, leading to inhibition of oncogenic transcriptional programs(7-9). Here we report the preferential sensitivity of TNBCs to BET bromodomain inhibition in vitro and in vivo, establishing a rationale for clinical investigation and further motivation to understand mechanisms of resistance. In paired cell lines selected for acquired resistance to BET inhibition from previously sensitive TNBCs, we failed to identify gatekeeper mutations, new driver events or drug pump activation. BET-resistant TNBC cells remain dependent on wild-type BRD4, which supports transcription and cell proliferation in a bromodomain-independent manner. Proteomic studies of resistant TNBC identify strong association with MED1 and hyper-phosphorylation of BRD4 attributable to decreased activity of PP2A, identified here as a principal BRD4 serine phosphatase. Together, these studies provide a rationale for BET inhibition in TNBC and present mechanism-based combination strategies to anticipate clinical drug resistance. |
format | Online Article Text |
id | pubmed-4854653 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
record_format | MEDLINE/PubMed |
spelling | pubmed-48546532016-07-06 Response and resistance to BET bromodomain inhibitors in triple negative breast cancer Shu, Shaokun Lin, Charles Y. He, Housheng Hansen Witwicki, Robert M. Tabassum, Doris P. Roberts, Justin M. Janiszewska, Michalina Huh, Sung Jin Liang, Yi Ryan, Jeremy Doherty, Ernest Mohammed, Hisham Guo, Hao Stover, Daniel G. Ekram, Muhammad B. Brown, Jonathan D'Santos, Clive Krop, Ian E. Dillon, Deborah McKeown, Michael Ott, Christopher Qi, Jun Ni, Min Rao, Prakash K. Duarte, Melissa Wu, Shwu-Yuan Chiang, Cheng-Ming Anders, Lars Young, Richard A. Winer, Eric Letai, Antony Barry, William T. Carroll, Jason S. Long, Henry Brown, Myles Liu, X. Shirley Meyer, Clifford A. Bradner, James E. Polyak, Kornelia Nature Article Triple negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy(1-3). BET bromodomain inhibitors, which have shown efficacy in several models of cancer(4-6), have not been evaluated in TNBC. These inhibitors displace BET bromodomain proteins such as BRD4 from chromatin by competing with their acetyllysine recognition modules, leading to inhibition of oncogenic transcriptional programs(7-9). Here we report the preferential sensitivity of TNBCs to BET bromodomain inhibition in vitro and in vivo, establishing a rationale for clinical investigation and further motivation to understand mechanisms of resistance. In paired cell lines selected for acquired resistance to BET inhibition from previously sensitive TNBCs, we failed to identify gatekeeper mutations, new driver events or drug pump activation. BET-resistant TNBC cells remain dependent on wild-type BRD4, which supports transcription and cell proliferation in a bromodomain-independent manner. Proteomic studies of resistant TNBC identify strong association with MED1 and hyper-phosphorylation of BRD4 attributable to decreased activity of PP2A, identified here as a principal BRD4 serine phosphatase. Together, these studies provide a rationale for BET inhibition in TNBC and present mechanism-based combination strategies to anticipate clinical drug resistance. 2016-01-06 2016-01-21 /pmc/articles/PMC4854653/ /pubmed/26735014 http://dx.doi.org/10.1038/nature16508 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Shu, Shaokun Lin, Charles Y. He, Housheng Hansen Witwicki, Robert M. Tabassum, Doris P. Roberts, Justin M. Janiszewska, Michalina Huh, Sung Jin Liang, Yi Ryan, Jeremy Doherty, Ernest Mohammed, Hisham Guo, Hao Stover, Daniel G. Ekram, Muhammad B. Brown, Jonathan D'Santos, Clive Krop, Ian E. Dillon, Deborah McKeown, Michael Ott, Christopher Qi, Jun Ni, Min Rao, Prakash K. Duarte, Melissa Wu, Shwu-Yuan Chiang, Cheng-Ming Anders, Lars Young, Richard A. Winer, Eric Letai, Antony Barry, William T. Carroll, Jason S. Long, Henry Brown, Myles Liu, X. Shirley Meyer, Clifford A. Bradner, James E. Polyak, Kornelia Response and resistance to BET bromodomain inhibitors in triple negative breast cancer |
title | Response and resistance to BET bromodomain inhibitors in triple negative breast cancer |
title_full | Response and resistance to BET bromodomain inhibitors in triple negative breast cancer |
title_fullStr | Response and resistance to BET bromodomain inhibitors in triple negative breast cancer |
title_full_unstemmed | Response and resistance to BET bromodomain inhibitors in triple negative breast cancer |
title_short | Response and resistance to BET bromodomain inhibitors in triple negative breast cancer |
title_sort | response and resistance to bet bromodomain inhibitors in triple negative breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854653/ https://www.ncbi.nlm.nih.gov/pubmed/26735014 http://dx.doi.org/10.1038/nature16508 |
work_keys_str_mv | AT shushaokun responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT lincharlesy responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT hehoushenghansen responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT witwickirobertm responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT tabassumdorisp responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT robertsjustinm responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT janiszewskamichalina responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT huhsungjin responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT liangyi responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT ryanjeremy responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT dohertyernest responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT mohammedhisham responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT guohao responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT stoverdanielg responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT ekrammuhammadb responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT brownjonathan responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT dsantosclive responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT kropiane responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT dillondeborah responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT mckeownmichael responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT ottchristopher responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT qijun responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT nimin responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT raoprakashk responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT duartemelissa responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT wushwuyuan responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT chiangchengming responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT anderslars responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT youngricharda responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT winereric responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT letaiantony responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT barrywilliamt responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT carrolljasons responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT longhenry responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT brownmyles responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT liuxshirley responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT meyerclifforda responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT bradnerjamese responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer AT polyakkornelia responseandresistancetobetbromodomaininhibitorsintriplenegativebreastcancer |